<SEC-DOCUMENT>0001193125-17-078871.txt : 20170310
<SEC-HEADER>0001193125-17-078871.hdr.sgml : 20170310
<ACCEPTANCE-DATETIME>20170310163255
ACCESSION NUMBER:		0001193125-17-078871
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170307
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170310
DATE AS OF CHANGE:		20170310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INTREXON CORP
		CENTRAL INDEX KEY:			0001356090
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36042
		FILM NUMBER:		17682574

	BUSINESS ADDRESS:	
		STREET 1:		1750 KRAFT DRIVE
		STREET 2:		SUITE 1400
		CITY:			BLACKSBURG
		STATE:			VA
		ZIP:			24060
		BUSINESS PHONE:		301-556-9809

	MAIL ADDRESS:	
		STREET 1:		1750 KRAFT DRIVE
		STREET 2:		SUITE 1400
		CITY:			BLACKSBURG
		STATE:			VA
		ZIP:			24060
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d339073d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): March&nbsp;10, 2017 (March 7, 2017) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>INTREXON CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Virginia</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-36042</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>26-0084895</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>20374 Seneca Meadows Parkway, Germantown, Maryland 20876 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(301) 556-9900 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;7, 2017, Geno J. Germano, President of Intrexon Corporation
(the &#147;Company&#148;), resigned from the Company effective March&nbsp;10, 2017, and Randal J. Kirk cancelled plans to transition to Executive Chairman and will remain Chairman and Chief Executive Officer of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01. Regulation FD Disclosure. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March 10, 2017, the Company announced the formation of Precigen, Inc., a wholly-owned subsidiary of the Company (&#147;Precigen&#148;), as
part of an ongoing evaluation of structural alternatives concerning the Company&#146;s business in healthcare. The Company currently intends to consolidate all health-related assets under this new corporate entity as it considers potential strategic
options to enhance shareholder value. A copy of the press release announcing Mr. Germano&#146;s resignation and the formation of Precigen is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this Item 7.01 is being furnished and shall not be deemed &#147;filed&#148; for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date of this Current Report on Form 8-K,
except as shall be expressly set forth by specific reference in such filing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release of Intrexon Corporation.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March&nbsp;10, 2017 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INTREXON CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Donald P. Lehr</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Donald P. Lehr</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Legal Officer</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release of Intrexon Corporation.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d339073dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g339073g0310224337613.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Intrexon Creates Precigen, Inc. and Accelerates Strategic Review of Structural Options Related to Health
Assets </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Geno Germano to Step Down as President; Randal Kirk to Remain CEO </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Executive Search Underway to Lead Precigen </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Germantown, MD, March</B><B></B><B>&nbsp;10, 2017</B> &#151;&nbsp;<U>Intrexon Corporation</U> (NYSE: XON), a leader in the engineering and
industrialization of biology to improve the quality of life and health of the planet, today announced the formation of Precigen, Inc., a wholly-owned subsidiary of the Company as part of an ongoing evaluation of structural alternatives concerning
its business in healthcare. Intrexon currently intends to consolidate all health-related assets under this new corporate entity as it considers potential strategic options to enhance shareholder value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;While we have been reviewing potential options for over a year, as our collaborators increasingly begin to move into the clinic, it is apparent that our
collection of health assets may be overshadowed by the breadth and complexity of the opportunities the engineering of biology has afforded us. We are therefore taking this structural action now to better position us for strategic decisions regarding
our health business moving forward,&#148; said Randal J Kirk, Intrexon&#146;s Chairman and CEO. &#147;Notably this structural move will have no impact on the programs of our collaborations in health or the pipeline of clinical stage product
candidates.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through utilization of Intrexon&#146;s proprietary technology platform, gene and cell therapy candidates in an array of therapeutic
areas including oncology, rare diseases, infectious diseases, ophthalmology, and cardiovascular disease are under development or have completed development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intrexon technology is currently being utilized in three ongoing clinical trials and as many as ten Investigational New Drug applications to be filed this
year. The clinical development pipeline for 2017 includes therapeutic candidates for advanced lymphoid malignancies, acute myeloid leukemia, pediatric brain tumors, solid tumors, oral mucositis, type 1 diabetes, wet
<FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration, <I>Clostridium difficile </I>infection, linear scleroderma, and cardiac disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Precigen will encompass all of Intrexon&#146;s health related collaborations, including its Exclusive Channel Collaborations and Research Collaborations,
Joint Ventures and its 75% ownership stake in its Xogenex subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Xogenex is developing what is believed to be the world&#146;s first three gene
approach to cardiac disease. Echocardiographic measurements in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> animal studies have demonstrated reversal of established ADM cardiomyopathy after a single treatment of Xogenex&#146;s lead
therapeutic candidate (P&lt;0.001). Nuclear localization of the phosphohistone H3 (PHH3) mitotic marker has also confirmed cardiomyocyte regeneration. Intrexon intends to file an IND on this ground-breaking program by year end. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intrexon also announced today that Geno Germano is stepping down as President, and Randal Kirk has cancelled
plans to transition to Executive Chairman and will remain Chairman and CEO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Germano stated, &#147;Since joining Intrexon I have had the unique
privilege to work alongside RJ Kirk, widely regarded as preeminent in the world of life science investing, at the company to which he has committed a huge portion of his personal energies as well as significant personal investment. RJ&#146;s vision
can be seen in the goals he sets and the tremendous resources - fiscal, technological and human - assembled to achieve them. It is with the foregoing in mind that it has become clear to me that RJ is integral to the day to day operation of this
company and that it is therefore appropriate for him to remain in the CEO role for the foreseeable future. At the same time, I have come to realize that my preference is to work within the industry where I spent most of my life, and therefore am
leaving the company to continue my career in the pharma/biopharma industry. I would like to take this opportunity to thank RJ and all the colleagues at Intrexon for the phenomenal opportunity they have given me to work at this fascinating
company.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Kirk added, &#147;In his short time with Intrexon, Geno has helped improve our company through the strengthening of
organizational processes and the recruitment of key executives. More than that, I want to note that Geno is an excellent man and someone I am pleased to call my friend. Regarding my own capabilities to lead this organization, I have never been so
committed to our goal, and I am acutely aware of the great responsibility placed on me and our whole team to achieve for our shareholders, our collaborators, and our customers.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intrexon has a search underway for an executive to lead Precigen. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Intrexon Corporation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intrexon Corporation (NYSE:
XON) is Powering the Bioindustrial Revolution with Better DNA<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> to create biologically-based products that improve the quality of life and the health of the planet.&nbsp;The Company&#146;s
integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells.&nbsp;We call
our synthetic biology approach Better DNA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, and we invite you to discover more at <U>www.dna.com</U> or follow us on Twitter at <U>@Intrexon</U>, on <U>Facebook</U>, and <U>LinkedIn</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Trademarks </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intrexon, Powering the Bioindustrial
Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of the statements made in
this press release are forward-looking statements.&nbsp;These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development
of our business.&nbsp;Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results
may be materially different from the plans, objectives and expectations expressed in this press release. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For more information regarding Intrexon Corporation, contact:</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact:</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Christopher Basta </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: +1 (561) <FONT
STYLE="white-space:nowrap">410-7052</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investors@intrexon.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marie Rossi, Ph.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Manager, Technical Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: +1 (301) <FONT
STYLE="white-space:nowrap">556-9850</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>publicrelations@intrexon.com</U> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g339073g0310224337613.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g339073g0310224337613.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ; .,# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
